Emerging Anticoagulant Drugs

Bates, Shannon M.; Weitz, Jeffrey I.

doi:10.1161/01.atv.0000084827.77945.66

Cited by 29 publications

(25 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…63 Phase III trials of treatment for acute VTE involving 2 of these agents have been completed. Fondaparinux (Arixtra) is a synthetic polysaccharide, based on the pentasaccharide sequence required to potentiate the anti-factor Xa activity of AT.…”

Section: Novel Antithrombotic Agents For the Initial Treatment Of Vtementioning

confidence: 99%

Initial Treatment of Venous Thromboembolism

McRae

Ginsberg

2004

Circulation

View full text Add to dashboard Cite

Abstract-Adequate initial anticoagulant therapy of deep venous thrombosis (DVT) is required to prevent thrombus growth and pulmonary embolism (PE). Intravenous unfractionated heparin (UFH) is being replaced by low-molecular-weight heparin (LMWH) as the anticoagulant of choice for initial treatment of venous thromboembolism (VTE). Both agents are relatively safe and effective when used to treat VTE, with LMWH suitable for outpatient therapy because of improved bioavailability and more predictable anticoagulant response. Serious potential complications of heparin therapy, such as heparin-induced thrombocytopenia (HIT) and osteoporosis, seem less common with LMWH. The potential for fetal harm and changes in maternal physiology complicate the treatment of VTE during pregnancy. Although systemic thrombolysis is used in patients with massive PE and in some patients with proximal DVT, controversy persists with respect to appropriate patient selection for this intervention. Key Words: venous thromboembolism Ⅲ pulmonary embolism Ⅲ deep venous thrombosis Ⅲ anticoagulants Ⅲ thrombosis Ⅲ heparin

show abstract

Section: Novel Antithrombotic Agents For the Initial Treatment Of Vtementioning

confidence: 99%

Initial Treatment of Venous Thromboembolism

McRae

Ginsberg

2004

Circulation

View full text Add to dashboard Cite

show abstract

“…15 It is formed from prothrombin (via factor Xa), and its major activity is in the final step of coagulation, where it cleaves fibrinopeptides from fibrinogen to form fibrin. 16 The procoagulant effects of thrombin can be blocked by inactivating the enzyme itself or by preventing its generation. 16,17 Ximelagatran (AstraZeneca), a pro-drug of melagatran, is an orally administered direct thrombin inhibitor.…”

mentioning

confidence: 99%

“…16 The procoagulant effects of thrombin can be blocked by inactivating the enzyme itself or by preventing its generation. 16,17 Ximelagatran (AstraZeneca), a pro-drug of melagatran, is an orally administered direct thrombin inhibitor. 15,16 It is rapidly absorbed from the gut and converted to its active form, melagatran.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Ximelagatran or Warfarin for Stroke Prevention in Patients With Atrial Fibrillation?

Hankey

Klijn

Eikelboom

2004

Stroke

View full text Add to dashboard Cite

“…The shortcomings of currently available anticoagulants have stimulated the search for new medicines for the prevention and treatment of thromboembolic disease [1], which is the primary cause of death in Western societies [2,3]. The need for well-tolerated anticoagulants that can be administered orally on an outpatient basis is particularly desirable given that many patients require daily anticoagulant therapy over the long term.…”

Section: Introductionmentioning

confidence: 99%